Developing new Russian drug for Corona virus announced

SANAA, Nov. 10 (YPA) – Alexander Gintsburg, the director of Gamaleya Research Center, Alexander Gintsburg — the developer of Sputnik V vaccine said that that a new drug is being developed to treat Coronavirus patients with antibodies.

“We will start clinical trials in January next year, and I hope we will pass these clinical trials in three to four months,” Alexander Gintsberg told the media.

The Russian Ministry of Health registered Sputnik V as the world’s first vaccine against Covid-19 in August 2020, developed by the Gamleya Center for Epidemiology and Microbiology Research and being produced in conjunction with the Russian Direct Investment Fund.

Test results for the Sputnik V vaccine showed a potency of more than 91.6 percent and a high safety rate, being given in two doses at a 21-day interval.

Sputnik V is one of the top three CORONA vaccines in the world in terms of the number of approvals obtained by government regulators. It has been registered by 50 countries, with a total population of more than 1.3 billion.

E.M